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1. General Information 
 
All reagents were purchased from commercial sources and used without further 
purification. POPC lipid was purchased from Avanti Polar Lipids. The POPC lipid was 
stored under Argon at -20°C and used within 3 months of purchase. Glassware was dried 
at 115°C overnight. Air and moisture-sensitive reagents were transferred using a syringe 
or stainless steel cannula. Intermediates were purified over silica (60Å, particle size 40-
63 µm) purchased from Dynamic Adsorbents, Inc. Reactions were monitored by thin-layer 
chromatography (TLC) using 0.25 mm silica gel plates (60F-254) from Dynamic 
Adsorbents, Inc. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories, Inc. 1H, 13C, 31P NMR spectra were obtained on either JEOL ECA 500 
spectrometer or Varian 400 MHz/500MHz spectrometer. Chemical shifts are reported in 
ppm relative to residual solvent. The FID file was analyzed using NMRnotebook version 
2.70 build 0.10 by NMRTEC.  
 
Dynamic Light Scattering (DLS) measurements were performed on a Wyatt DynaPro 
NanoStar (Wyatt Technology, Santa Barbara, CA) instrument using a disposable cuvette 
(Eppendorf UVette 220 nm – 1,600 nm) and data processed using Wyatt DYNAMICS V7 
software. Each analysis involved an average of 10 measurements. The data was 
exported for final plotting using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA). 
 
Low resolution MS analysis was performed on a Micromass Quattro Ultima triple 
quadrupole mass spectrometer with an electrospray ionization (ESI) source. High 
resolution MS analysis was performed using Agilent 6230 Accurate-Mass TOFMS with 
an electrospray ionization (ESI) source by Molecular Mass Spectrometry Facility (MMSF) 
in the department of chemistry and biochemistry at University of California, San Diego.  
 
Fluorescence decay measurements were taken on a Perkin Elmer Enspire© multimode 
plate reader (excitation 485 nm, emission 517 nm and 75 flashes); each measurement 
was taken with a 10 sec delay with 125 repeat (total acquisition time = 21 min). Costar 
EIA/RIA plates were used (96 well half area, no lid, flat bottom, non-treated black 
polystyrene). The data were exported for final plotting using GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, CA). 
 
HPLC analyses were performed using an Agilent 1100 Series HPLC and an analytical 
reverse-phase column (Eclipse XDB-C18 Agilent, 5 µm, 150 x 4.6 mm). Flow: 1 mL/min. 
Injection volume = 50 µL. Detection: 254 and 280 nm. Mobile phase: water/acetonitrile 
containing 0.1% (v/v) trifluoroacetic acid (TFA).  
Method A: Linear gradient from 5% to 95% of ACN in 10 minutes followed by 2 minutes 
of re-equilibration at 5% of ACN. 
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2. Synthesis of GcGTPC-CH lipid  
 
FIgure S1. Synthetic scheme to generate GcGTPC-CH 
2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethan-1-ol (1) 
Compound 1 was prepared following a previously reported 
protocol.[1] 
 
2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethyl 4-methylbenzenesulfonate (1.1) 
Compound 1.1 was prepared following a previously reported 
protocol.[1] 
 O
H
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5-(2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethoxy)-2-phenyl-1,3-dioxane (1.2) 
To a cooled suspension of 0.27 g (11 mmol) of NaH in 5 mL 
of dry tetrahydrofuran (THF), 0.67 g (3.7 mmol) of cis-1,3-O-
Benzylideneglycerol was added drop wise and reacted for 1 
hour at room temperature. Next, 1.97 g (4.1 mmol) molecule 
1.1 was added and then heated at reflux for 16 hours. The 
reaction was quenched with water and the solvent was removed under vacuum. The 
residue was extracted with DCM, washed successively with water and brine, then dried 
over MgSO4 and compound 1.2 was obtained as a white solid and then engaged to the 
next step.  
3-(benzyloxy)-2-(2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-
2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-yl)oxy)ethoxy)propan-1-ol (2) 
 1.57 g (2.7 mmol) of 1.2 was dissolved in 7.5 mL of dry 
dichloromethane (DCM) then cooled to -78 °C. 7.7 mL of DIBAL-
H in DCM (1 M) was added dropwise and the reaction was 
slowly brought back to room temperature and reacted for 16 
hours. The reaction was quenched with methanol and 27 mL of 
(5 M) NaOH was added. The solution was then extracted with diethyl ether, washed 
successively with water and brine, then dried over MgSO4 and purified by column 
chromatography on silica gel using Hexane/EtOAc (1:1) as the eluent. Compound 2 was 
obtained as a white oily solid (1.39 g, 88%). 
Rf: 0.59 (Hexane/EtOAc 1:1); 1H NMR (500 MHz, CDCl3-d1) δ 7.28-7.17 (m, 5H), 5.27-
5.26 (m, 1H), 4.46 (s, 2H), 3.82-3.80 (m, 1H), 3.63-3.38 (m, 9H), 3.18-3.08 (m, 1H), 2.34-
2.27 (m, 1H), 2.17-2.11 (m, 1H), 1.96-1.72 (m, 5H), 1.51-1.18 (m, 11H), 1.09-0.78 (m, 
22H), 0.61 (s, 3H); 13C NMR (126 MHz, CDCl3-d1) δ 140.5, 138.1, 128.3, 127.6, 127.6, 
121.7, 80.2, 80.2, 79.5, 73.4, 70.3, 70.2, 70.1, 67.6, 67.5, 62.7, 56.7, 56.2, 50.1, 42.3, 
39.8, 39.5, 38.9, 37.1, 36.8, 36.2, 35.8, 31.9, 31.8, 28.3, 28.0, 24.3, 23.9, 22.9, 22.6, 21.1, 
19.4, 18.8, 11.9; ESI-MS: 617.53 [M+Na]+; HRMS 617.4540 calcd for [C39H62O4Na]+, 
found 617.4534. 
 
(1R,3S)-1,3-bis(14-bromotetradecyl)cyclohexane (3) 
Compound 3 was prepared following a previously reported 
protocol.[2] 
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(3R,8R,9R,10S,13S,14R)-3-(2-((1-(benzyloxy)-3-((12-((1S,3R)-3-(13-(3-(benzyloxy)-2-
(2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethoxy)propoxy)tridecyl)cyclohexyl)dodecyl)oxy)propan-2-yl)oxy)ethoxy)-10,13-
dimethyl-17-((S)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthrene (4) 
To a cooled suspension of 0.08 g (3.2 
mmol) of NaH in 34 mL of dry THF, 1.39 g 
(2.3 mmol) of 2 was added drop wise and 
reacted for 1 hour at room temperature. 
Next, 0.64 g (1.1 mmol) molecule 3 was added and then heated at reflux for 16 hours. 
The reaction was quenched with water and the solvent was removed under vacuum. 
The residue was extracted with DCM, washed successively with water and brine, then 
dried over MgSO4 and purified by column chromatography on silica gel using 
Hexane/EtOAc (9:1) as the eluent. Compound 4 was obtained as a clear oil (0.441 g, 
29%).  
Rf: 0.15 (Hexane/EtOAc 9:1); 1H NMR (500 MHz, CDCl3-d1) δ 7.33-7.25 (m, 10H), 5.32-
5.31 (m, 2H), 4.55 (s, 4H), 3.76-3.74 (m, 4H), 3.723.58 (m, 2H), 3.63-3.49 (m, 12H), 
3.42 (t, J = 6.7 Hz, 4H), 3.22-3.14 (m, 2H), 2.38-2.35 (m, 2H), 2.21-2.16 (m, 2H), 2.03-
1.81 (m, 10H), 1.72-1.68 (m, 4H), 1.55-1.42 (m, 14H), 1.31-0.74 (m, 105 H), 0.67 (s, 
6H), 0.51-0.44 (m, 1H); 13C NMR (126 MHz, CDCl3-d1) δ 141.2, 138.6, 128.5, 127.8, 
127.7, 121.7, 79.6, 78.7, 73.6, 71.9, 70.9, 70.5, 70.2, 68.2, 67.7, 57.0, 56.4, 50.4, 42.5, 
40.8, 40.0, 39.7, 39.3, 38.0, 37.9, 37.4, 37.1, 36.4, 36.0, 33.6, 32.1, 32.1, 30.3, 30.0, 
29.9, 29.7, 28.6, 28.4, 28.2, 27.2, 26.6, 26.3, 25.8, 24.5, 24.0, 23.0 ,22.8, 21.3, 19.6, 
18.9, 12.1; ESI-MS: HRMS  1656.3883 calcd for [C110H184O8Na]+, found 1656.3879. 
 
2-(2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethoxy)-3-((13-((1R,3S)-3-(13-(2-(2-(((3R,8R,9R,10S,13S,14R)-10,13-dimethyl-
17-((S)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)oxy)ethoxy)-3-
hydroxypropoxy)tridecyl)cyclohexyl)tridecyl)oxy)propan-1-ol (5) 
 35 mg (0.022 mmol) of 4 and 1.8 mg (5 % 
w/w) of Pd(OH)2 was added to 4 mL of 
solvent mixture THF/EtOH (1:1). The 
suspension was purged with N2 gas for 10 
seconds and repeated 3 times. The suspension was then purged using H2 for 10 
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seconds and repeated 3 times. The reaction was stirred at room temperature for 20 
mins. The suspension was then immediately filtered over celite and purified using 
column chromatography on silica gel using Hexane/EtOAc (7:3) as the eluent. 
Compound 5 was obtained as a white viscous oil (20.3 mg g, 65%).  
Rf: 0.13 (Hexane/EtOAc 7:3); 1H NMR (500 MHz, CDCl3-d1) δ 5.27-5.26 (m, 2H), 3.86-
3.81 (m, 2H), 3.64-3.34 (m, 20H), 3.18-3.11 (m, 2H), 2.32-2.27 (m, 2H), 2.18-2.11 (m, 
2H), 1.96-1.73 (m, 10H), 1.65-1.59 (m, 4H), 1.50-1.38 (m, 14H), 1.27-0.65 (m, 105H), 
0.59 (s, 6H), 0.044-0.38 (m, 1H); 13C NMR (126 MHz, CDCl3-d1) δ 140.9, 122.0, 80.3, 
80.3, 79.8, 72.0, 71.2, 70.4, 70.4, 67.8, 67.7, 63.3, 57.0, 56.4, 50.4, 42.5, 40.8, 40.0, 39.7, 
39.1, 39.1, 38.0, 38.0, 37,4, 37.1, 36.4, 36.0, 33.7, 32.1, 32.1, 30.3, 30.0, 29.9, 29.8, 29.7, 
28.5, 28.5, 28.4, 28.2, 27.2, 26.6, 26.3, 24.5, 24.0, 23.0 22.8, 21.3, 19.6, 18.9, 12.1; ESI-
MS: 1476.28 [M+Na]+; HRMS 1476.2944 calcd for [C96H172O8Na]+, found 1476.2952. 
 
2-(2-(((3S,8S,9S,10R,13R,14S)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)oxy)ethoxy)-3-((13-((1R,3S)-3-(13-(2-(2-(((3R,8R,9R,10S,13S,14R)-10,13-dimethyl-
17-((S)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)oxy)ethoxy)-3-((oxido(2-
(trimethylammonio)ethoxy)phosphoryl)oxy)propoxy)tridecyl)cyclohexyl)tridecyl)oxy)prop
yl (2-(trimethylammonio)ethyl) phosphate (GcGTPC-CH) 
To a solution of 81 mg (0.34 mmol) of 
bromoethyldichlorophosphate in 1.5 mL of 
dry THF, a solution of 61 mg (0.04 mmol) of 
5 and 64 µL of Et3N (0.46 mmol) in 1.5 mL 
of dry THF was added dropwise. After 
stirring the mixture for 3 days in the dark at 
room temperature, toluene was added to 
precipitate triethylammonium chloride. 
Then, the solution was filtered through a small pad of celite and the filtrate was 
concentrated. The resulting residue was dissolved in a mixture of THF/NaHCO3 (sat) (2.8 
mM) and the reaction was stirred for 16 hours at room temperature. THF was evaporated 
under vacuum and the resulting aqueous solution was acidified to pH 1 using a dilution 
solution of hydrochloric acid (1M) and extracted using several portions of DCM/Methanol 
(MeOH) (8:2). The organic layers were combined, dried over Na2SO4 and concentrated 
under reduced pressure. 
To a solution of the previous crude in a mixture of 3.5 mL of chloroform (CHCl3) and 4 mL 
of Me3N (33% in EtOH) was added and the reaction was stirred in a sealed tube at room 
temperature for 5 days. The reaction mixture was concentrated to dryness, purified on 
sephadex LH-20 using DCM/MeOH (1:1) as eluent and purified by column 
chromatography on silica gel using DCM/MeOH/Water (70:30:5) as the eluent. GcGTPC-
CH was obtained as a white (viscous oil) (40 mg, 53%).  
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Rf: 0.15 (Hexane/EtOAc 9:1); 1H NMR (500 MHz, MeOD-d4/CDCl3-d1 1:1) δ 4.99-4.95 (m, 
2H), 3.92-3.85 (m, 4H), 3.57-3.52 (m, 4H), 3.43-3.33 (m, 6H), 3.29-3.05 (m, 16H), 2.97-
2.94 (m, 2H), 2.85-2.84 (m, 18H), 2.00-1.77 (m, 4H), 1.67-1.44 (m, 10H), 1.34-1.32 (m, 
4H), 1.19-1.07 (m, 15H), 0.98-0.32 (m, 110H), 0.16-0.08 (m, 1H); 13C NMR (126 MHz, 
CDCl3-d1) δ 140.2, 121.4, 79.1, 78.3, 78.2, 71.3, 70.3, 69.6, 67.1, 66.0, 64.8, 64.8, 58.6, 
58.6, 56.5, 55.9, 53.5, 49.9, 41.9, 40.2, 39.5, 39.1, 38.7, 37.4, 36.8, 36.4, 35.8, 35.5, 33.1, 
31.6, 31.5, 29.7, 29.4, 29.3, 29.2, 28.0, 27.8, 27.6, 26.6, 26.0, 25.8, 23.9, 23.4, 22.1, 21.9, 
20.7, 18.8, 18.1, 11.3; 31P NMR (202 MHz, MeOD-d4/CDCl3-d1 1:1) δ 0.12; HRMS 
1784.4235 calcd for [C106H197N2O14P2]+, found 1784.4264. 
 
3. General Procedure for Liposome Extrusion 
 
10 mg/mL liposome solution was prepared by first dissolving 5 mg of lipid of interest into 
a 5 mL round bottom flask in a DCM/MeOH (7/3) solution. A thin lipid film was achieved 
by evaporating the solvent using a rotary evaporator (BUCHI RE111) then dried further 
over a hi-vacuum pump (Welch 1402) for 4 hrs. The thin lipid film was then hydrated, in 
either 100 mM/4 mM Carboxyfluorescein (CF) or 10 mM calcein solution prepared in PBS 
or buffer A/C or (see section 5, general buffer preparation procedure) respectively, by 
vortexing the solution for 30 seconds followed by sonication in a water bath sonicator 
(Branson 2510) for 30 mins. After sonication, the lipid mixture underwent 5 freeze thaw 
cycles that consisted of 2 mins at -78°C followed by 2 mins at 50°C. The lipid solution 
was then extruded (Avanti mini-extruder) through 200 nm polycarbonate membrane 25 
times followed by another extrusion with a 100 nm polycarbonate membrane 51 times. 
The lipid solution was then stored at 4°C in Protein Lo-Bind Eppendorf tube. 
 
4. General Procedure for Differential Scanning Calorimetry (DSC) Measurement of 
GcGTPC-CH lipid 
 
DSC experiments were performed in duplicate using a Thermal Analysis Q2000 DSC. 
Each experiment involved a 5 °C/min ramp from 0 °C to 67 °C under high purity N2 at 50 
mL/min. Samples were ~0.3 – 1.0 mg of liposomes dissolved in water at ~5% by weight. 
TA Universal Analysis was used to extract Tm for these samples. Both of the synthetic 
lipids did not exhibit a phase transition from 5 - 65 °C (Figure S2). DMPC was used as a 
positive control in the DSC measurements, which showed the expected phase transition 
at 24 °C. Commercially available diacyl lipid, POPC, was reported to have a phase 
transition from solid to liquid at -2 ºC.[3] 
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Figure S2. Differential scanning calorimetry traces of lipids 
 
5. General Buffer Preparation Procedure 
 
Preparation of Buffer A- 4.18 g of Bis Tris (10 mM) and 11.68 g of NaCl (100 mM) was 
dissolved in 2 L of Milli-Q filtered deionized water. The pH was then adjusted to 7.2 by 
minimal addition of 2 M HCl. 
 
Preparation of Buffer B - 4.18 g of Bis Tris (10 mM) and 11.68 g of NaCl (100 mM) was 
dissolved in 2 L of Milli-Q filtered deionized water. The pH was then adjusted to 5.8 by 
minimal addition of 2 M HCl. 
 
Preparation of Buffer C – 5.2 g of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES) (10 mM) and 17.5 g of NaCl (150 mM), were dissolved in 2 L of Milli-Q 
filtered deionized water. The pH was then adjusted to 7.4. 
Preparation of Buffer D – 0.46 g of 2-[(2-Hydroxy-1,1-
bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid, N-[Tris(hydroxymethyl)methyl]-2-
aminoethanesulfonic acid (TES) (2 mM), 5.84 g of NaCl (100 mM), 0.029 g of 
ethylenediaminetetraacetic acid (EDTA) (0.1 mM), and 0.31 g of histidine (2 mM) was 
dissolved in 1 L of Milli-Q filtered deionized water. The pH was then adjusted to 7.4. 
Preparation of Buffer E – 0.23 g of TES (2 mM), 2.11 g of NaCl (72.23 mM), 0.62 g of 
CaCl2 (11.11 mM), 0.015 g of EDTA (0.1 mM), and 0.16 g of histidine (2 mM) was 
dissolved in 0.5 L of Milli-Q filtered deionized water. The pH was then adjusted to 7.4. 
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6. General Procedure to Measure pH Equilibrium of CF 
 
CF was used as the reporter dye because CF is a pH responsive fluorophore and is 
known to exhibit fluorescence quenching upon acidification. We chose the pH values of 
7.2 to 5.8 as internal and external liposomal pH values, respectively, because CF exhibits 
a linear correlation between its fluorescence intensity and environmental pH value with in 
this pH range.[4]  
 
To estimate the initial rate of pH equilibration from liposomes, the decrease in 
fluorescence of CF was followed using Perkin Elmer Enspire© multimode plate reader. 
Before each assay, 10 µL of the stock extruded lipid solution was diluted in 500 µL of 
buffer A. Free CF was removed using a PD miniTrapTM G-25 SephadexTM column from 
GE Healthcare ending in 100 times dilution from the stock extruded solution (0.1 mg/mL). 
45 µL of purified liposome solution was next added into three 0.5 mL Protein Lo-Bind 
tubes for each lipid solution. In one tube, 405 µL of Buffer A was added. In the second 
tube, 400 µL of Buffer B was added with 5 µL of 100 µM solution of Nigericin in Ethanol. 
Nigericin, a polyether ionophore known to form pores in membranes, was used as our 
positive control of complete pH exchange between the internal/external buffer systems. 
In the third tube, right before starting the measurement, 405 µL of Buffer B was added. 
125 µL was added to each well of the plate three times for each tubes resulting in three 
measurements with three replicates with a total of 9 measurements per lipid solution. No 
significant morphology change was observed after 5 hours (shown in Figure S3). 
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Figure S3. Dynamic light scattering (DLS) measurements of liposomes 
 
7. General Calculation Procedure for Kinetic Analysis 
 
For the pH equilibration leakage assay, the relative fluorescence (Frel) of CF was 
normalized using equation (1). F0 represents fluorescence at time 0, FA represents 
fluorescence measurements at different times, and FNig is the fluorescence measurement 
of the liposome solution including Nigericin at 600 second in buffer B. After the data was 
normalized, equation (2) was used to determine the rate of decrease in CF fluorescence 
by combining individual measurements using GraphPad Prism 5 software. Additional 
experiments that collected more data points (up to 0.35 hours) were performed for 
liposomes made with pure POPC to obtain a more accurate calculated observed rate 
using initial rates. (shown in Figure S4). 
 
    𝐹"#$ = 1 − ()	+	(,(()	+	(./0) 	𝑋	100	   (1) 
 
 
    𝑙𝑛	(𝐹"#$) 	= 	−𝑘𝑡	     (2) 
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Figure S4. Average plot of 9 technical repeat experiments of % CF fluorescence vs. time (h)  
 
 
8. Gemcitabine leakage experiment 
The in vitro leakage of the gemcitabine (GEM) from liposomes was measured using a 
dialysis assay. Briefly, GEM encapsulated liposomes were made by weighing 10 mg of 
lipid and 40 mol% of cholesterol (only for POPC and GMGTPC-CH) into a 5 mL round 
bottom flask and dissolved in 1:1 chloroform/methanol. The solvent was evaporated via 
vacuo to form a lipid film and hydrated with 500 µL of 60 mM GEM in Buffer C. 50 µL of 
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the stock liposomal formulation (20 mg/mL) was diluted with buffer C to 500 µL and 
purified using sephadex G-25 to prepare a 1 mL working solution. The purified 
liposomal suspensions was placed in a dialysis device (Slide-A-Lyzer® Mini dialysis, ref 
88405, Thermo Scientific) with a molecular weight cutoff of 20 kDa and dialyzed against 
42.5 mL of buffer C at 37 °C and shaken on an orbital shaker (50 rpm). At various time 
points, aliquots (40 μL) were withdrawn from the dialysis compartment and retention of 
encapsulated drug was measured by HPLC. 
To a vial, 40 μL of a Triton solution (0.5 % w/v in HBS) was added to 40 μL of liposomal 
suspension. The samples were vortexed and analyzed by HPLC using method A for the 
detection of GEM. Data was analyzed using Agilent analysis software (Chemstation®). 
For each time point, the percentage of drug remaining in the liposomes was calculated 
using the following equation (3): 𝑅𝑒𝑡𝑎𝑖𝑛𝑒𝑑	𝑑𝑟𝑢𝑔	(%) = 100× B"#C(D)B"#C	(DE)  (3) 
 
9. Molecular Dynamics Simulations and Analysis 
Lipids were first constructed using Maestro (Schrödinger LLC, New York, NY).  
Membranes containing 729 lipids were then built and solvated using TIP3P water using 
VMD[5].  Each system was minimized and heated in 75 K steps, reaching a final 
temperature of 300 K.  Following about 20 ns of equilibration, MD simulations for all 
membrane systems were performed for 100 ns under isothermal-isobaric (NpT) 
conditions. The temperature was maintained by using the Nose-Hoover chain method 
and the pressure was maintained at 1 atm. The CHARMM36 force field was used with a 
10 Å cut-off for van der Waals with an 8.5 Å switching distance, and Particle Mesh 
Ewald for long-range electrostatics. All the simulations were carried out using NAMD[6], 
and post-simulation trajectory analysis was carried out using both VMD, R (http://www.r-
project.org), and the Bio3D package[7,8].   
To identify the number of water molecules in the core of the membrane, we used 
methods described previously[9]. In short, we identified water molecules that penetrated 
past the head groups and into the carbon-rich region of the membrane, i.e. between the 
ether or ester oxygens of the head groups on either side of the membrane.  The 
calculation was performed in a grid fashion across the full membrane and the results 
reported were the total number of waters within the membrane for each snapshot over 
the final 50 ns of the trajectory shown in Figure S5. 
13	
	
Figure S5. Total number of waters within the membrane for each snapshot over the final 50 ns of the trajectory 
 
10. General Procedure for Monitoring Gramicidin A Activity In Liposomes 
 
Liposomes were prepared as described in general procedures for liposome extrusion. 
The general procedure to measure pH equilibrium of CF was used with a small 
modification. After the liposomes were prepared, a solution of gA was prepared 225 µM 
in DMSO. To each tube (i.e. pH 7.2, pH 5.8, pH 5.8 + nigericin) 2 µL of buffer A was 
added to control the volume. Additional solution containing 2 µL of DMSO (vehicle) or 2 
µL gA (final concentration of 1 µM) was incubated at 37 ºC with liposomes for 30 
minutes and CF fluorescence was measured and analyzed. As shown in Figure S6A, no 
significant effect was observed when 2 µL of DMSO was added. The decrease in 
percent fluorescence of CF shown in Figure S5A suggests that gA was able to form a 
channel on the membrane to allow ions to rush inside. DLS measurements were taken 
to confirm the presence of liposomes after the addition of DMSO and gA, as shown in 
Figure S6B.  
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Figure S6. Effect of gramicidin A on GcGTPC-CH liposomes. A) Percent fluorescence of CF after incubation with or without gA at 
37 ºC for 30 minutes. B) DLS measurements of GcGTPC-CH liposomes under different conditions.  
 
11. General Procedure for phospholipase-D induced cleavage of choline 
 
Liposomes were prepared as described in general procedures for liposome extrusion. 
The liposomes were first hydrated in buffer D, then the liposome formulation was 
incubated in buffer E with or without 5 units of PLD from cabbage (Sigma Aldrich) at 37 
ºC for 30 minutes. After incubation, the liposome size was measured using dynamic 
light scattering (DLS) to study whether a morphology change occurred. As shown in 
Figure S7A, GcGTPC-CH liposomes without added PLD show a consistent size 
measured using DLS for 10 acquisitions after 30 mins at 37 ºC. However, as shown in 
Figure S7B, the size of GcGTPC-CH liposomes with added PLD after 30 mins 37 ºC 
shows a large variability in the liposomal diameter among the 10 acquisitions. The 
greater degree of variability is most likely caused by the inability of the DLS instrument 
to size particles with a great degree of multimodal size distributions caused by the 
destabilization of the liposomes through aggregation/fusion events.   
Additionally, PLD activity was confirmed using a commercially available phosphorus 
assay kit (Sigma, MAK122) according to the manufacturers protocol. We estimated the 
percent choline released, which is directly correlated with the phosphorus concentration, 
by normalization to the phosphorus concentration obtained by the Bartlett assay.  
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Figure S7. 10 DLS acquisition measurements. A) 10 DLS acquisition measurements without added PLD of GcGTPC-CH liposomes. 
B) 10 DLS acquisition measurements with added PLD of GcGTPC-CH liposomes. 
 
 
12. General Procedure for self-quenched CF liposomal release assay in serum 
 
Liposomes prepared as described in general procedures for liposome extrusion. Using 
the method of self-quenched CF loaded (100 mM in PBS) leakage assay[10], liposomes 
comprised of GcGTPC-CH (using general procedure for liposome extrusion) were 
incubated in PBS with 30 % fetal bovine serum (FBS) at 37 ºC (final liposome dilution of 
1000 times from stock extruded solution) and CF fluorescence was monitored (Ex 485 
nm/Em 517) nm for up to 5 days.  
 
 
13. General procedure for cellular uptake of small molecule entrapped in 
GcGTPC-CH liposomes 
	
13.1. Cell toxicity studies of GcGTPC-CH liposomes 
 
KB cells were plated onto a fibronectin-treated 96 well plate at 5000 cells/well in folate 
deficient Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen). The cells 
were incubated for 24 hours under a humidified atmosphere of 95% air and 5% CO2 at 
37°C. After 24 hours of incubation, the cells were dosed with various concentrations of 
the liposomes, in triplicate. The cells were incubated with the liposomes for 24 hours, 
and then washed to remove unbound compound. After incubation with the liposomes, 
the cells were carefully washed three times with 200 mL phosphate buffered saline 
(PBS) buffer and fixed with a solution of 200 µL PBS and 50 mL of 50% trichloroacetic 
acid. The cells were allowed to fix at 4°C for 1 hr. After fixation, the cells were washed 
five times with water and allowed to dry. After the plates are dried, 100 mL of a 0.4 % 
sulforhodamine B (SRB, Sigma Aldrich, S1402) solution in 1% acetic acid was added to 
each of the wells and incubated for 30 minutes at room temperature on a shaker. The 
SRB-treated cells were then washed five times with 1 % acetic acid and allowed to dry. 
Tris base solution (100 mM, 200 mL) was then added to each well and the plates were 
placed on an oribital shaker for 30 minutes. The plates were then read on a microplate 
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reader at 515 nm. The absorbance values were used to create cell-toxicity curves. 
Liposomes showed no toxicity up to 100 µM, as shown in Figure S8. 
 
Figure S8. KB cell viability with varying concentration of liposome. 
13.2. Fluorescence microscopy of GcGTPC-CH liposome uptake  
To a dry lipid film of GcGTPC-CH lipid with added 0.5 mol % of DSPE-PEG2000-folate 
lipid, 10 mM calcein in buffer A was then used to hydrate the lipid film. Liposomes were 
then prepared as described in general procedures for liposomes extrusion. 
KB cells were plated with folate deficient RPMI-1640 media supplemented with 10% 
fetal bovine serum (FBS) on 10mm glass bottom plates and incubated for 12 hours. 
Media was then removed and a solution containing 10 µM of liposomes, free calcein, or 
PBS control was added to the cells and incubated for 6 hours. Cells were then rinsed 
with media once, and a fresh media containing 2 µg/mL Hoescht nuclear stain was 
added. The living cells where then immediately imaged with an Olympus FluoView 
FV1000 deconvolution IX81 inverted confocal microscope equipped with a 405, 488, 
and 543 laser line. Fluorescence images were processed with ImageJ shown in Figure 
S9. 
 
	
 
Figure S9. Cell images after cells were incubated with liposomes, free calcein, and vehicle.  Scale	bar	=	20	µm	
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14. NMR Spectra  
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